U.S. Markets closed

Bio-Techne Corporation (TECH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
116.93-0.02 (-0.02%)
At close: 4:00PM EDT

116.93 0.00 (0.00%)
After hours: 6:12PM EDT

People also watch

Bio-Techne Corporation

614 McKinley Place NE
Minneapolis, MN 55413
United States

Full Time Employees1,560

Key Executives

Mr. Charles R. KummethChief Exec. Officer, Pres and Director2.06MN/A57
Mr. James T. HippelChief Financial Officer and Sr. VP855.7kN/A46
Mr. N. David EansorSr. VP of Biotech Division690.06kN/A56
Mr. Robert M. GavinSr. VP of Protein Platforms DivisionN/AN/A49
Mr. Kevin S. GouldSr. VP of Diagnostics Division425.26kN/A51
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company operates through three segments: Biotechnology, Clinical Controls, and Protein Platforms. The Biotechnology segment provides proteins, such as cytokines, growth factors, and enzymes; polyclonal antibodies in goats, sheep, and rabbits, as well as monoclonal antibodies; microtiter-plate based kits, immunoassays based on encoded bead technology and planar spotted surfaces, and microfluidic-based immunoassays to quantify the level of a specific protein in biological fluids; and erythropoietin, transferrin receptor, and Beta2-microglobulin immunoassays for use as in vitro diagnostic devices. This segment also offers fluorochrome labeled antibodies and kits to determine the immuno-phenotypic properties of cells from various tissues; and natural or synthetic chemical compounds for use as agonists, antagonists, and/or inhibitors of various biological functions. The Clinical Controls segment provides hematology controls and calibrators for hematology clinical instruments; clinical controls for blood glucose and blood gas devices, as well as coagulation device control products; and bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry. The Protein Platforms segment develops, manufactures, and sells tools comprising Simple Western platform, an assay for protein analysis and identification; SimplePlex platform, an assay used in research and clinical diagnostics; and Biologics Instrumentation to interrogate protein purity and identify contaminants during the development and production of biologics. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Corporate Governance

Bio-Techne Corporation’s ISS Governance QualityScore as of July 1, 2017 is 3. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.